Kornimate/medical-research-clean huggingface dataset:
nasal irrigation to reduce covid-19 morbidity

Conditions: Covid19

Summary: the purpose of this study is to evaluate if using nasal irrigation, also known as nasal lavage, for 14 days after a positive test in high risk patients can reduce the severity of symptoms associated with covid-19. nasal lavage consists of running salt water in one nostril and out the other to get rid of germs. nasal irrigation was done with either betadine or baking soda to determine if adding an antimicrobial or changing the ph of the mucous helped. hospitalization and death were compared for combined nasal irrigation groups to the cdc dataset of patients aged 50+

the purpose of this study is to evaluate if using nasal irrigation, also known as nasal lavage, can reduce the severity of symptoms associated with covid-19. nasal lavage consists of running salt water in one nostril and out the other to get rid of germs. saline nasal irrigation with betadine or baking soda will be evaluated. participants will be asked to do several things during this study: watch a one minute video on youtube, use a nasal irrigation device twice a day for 14 days, complete a one-time detailed survey and keep a research diary about their usage and symptoms using an on-line application called qualtrics, agree to be texted reminders, be called on the phone if they fail to complete the daily diary two days in a row, agree to be called four times, and provide contact information for a secondary person who can be contacted if the primary participant is unavailable. participation in this study does not involve any significant risks. however, some people may find using nasal irrigation causes them some discomfort. while there are no known benefits to participating in the study participants may see a reduction in their symptoms more quickly than if they didn't participate in the study.

Eligibility criteria:
inclusion criteria: * capable of understanding and providing informed consent using remote consent * willingness and physical capacity to initiate nasal irrigation and to adhere to the protocol * willing to give additional contact phone number of another person who will know the health status of the participant and agree to be contacted if needed for follow-up * 55 years of age or older * has access to and the willingness and ability to adhere to the technological requirement of the study i.e. able to use a smartphone for voice and text and email and access to the internet at home * english speaking * positive rapid covid-19 test performed the day of or the day before enrollment exclusion criteria: * currently doing daily nasal irrigation * current supplemental oxygen therapy * unwillingness to try nasal irrigation or use nasal irrigation twice a day * nasal surgery within the past year or chronic sinusitis * prior covid-19 infection or positive test \>1 day before present * symptoms longer than 7 days prior to testing as reported to researchers * allergy to iodine or shellfish * participation in another prospective covid related research project (clinical trial). * employed and working as a healthcare worker.

Keywords: prevention nasal lavage povidone-iodine
ultrasound elastography application in cesarean section scar defect

Conditions: Cesarean Section; Dehiscence

Summary: cesarean section scar defect(csd) is one of the complications after cesarean section. csd will cause many long term complications, such as abnormal uterine bleeding, infertility, uterine scar pregnancy and uterine rupture. transvaginal ultrasound was used to detect uterine scar defects commonly. ultrasound elastography is a modern imaging technique that has developed rapidly in recent years. thus, this study intend to investigate the application of ultrasound elastography in cesarean section scar defect.


Eligibility criteria:
inclusion criteria: * clearly diagnosed with csd * no serious medical problems (important viscera function in the normal range). uterine fibroids no more than 5cm * sign the informed consent. exclusion criteria: * indefinite diagnosis. * malignant tumors. * with severe medical problems (severe liver disease, kidney disease, respiratory diseases, heart disease or uncontrolled diabetes, epilepsy, etc., dysfunction of important organs). * pregnant. * mental diseases. * unwilling to comply with the research plan.
does autologous fat transplantation improve results and reduce complications in breast reconstruction with implants?

Conditions: Breast Neoplasms

Summary: the purpose of this study is to determine if autologous fat transplantation as a pre-treatment gives better results in breast reconstruction with implants after mastectomy and radiotherapy. one group is randomized to conventional reconstruction with implant and one to pre-treatment prior reconstruction with implant. our aims are: 1. to study whether lipofilling can decrease the number of reoperations and complications such as postoperative infections or not. 2. evaluate the aesthetic results and the patients' experiences. for both these aims the hypothesis is that pre-treatment is in favour for the outcomes.

all patients will undergo breast reconstruction with expander implant. half of the patients will be randomized to pre-treatment with lipofilling before the reconstruction. the randomization will be carried out with block randomization. a certain person that has not met the patients has been assigned to do this. fat transplantation: the fat will be harvested manually with dry technique using a coleman cannula on a 10 ml syringe. there after the syringes and fat are centrifuged at 3000 rpm for 3 minutes. liquid fat from lysed cells and blood will be separated from the purified fat cells and discarded. the fat graft will then be injected fan-shaped in multiple layers into the subcutaneous tissues of the breast using another blunt cannula with a diameter of 1.29 mm. if necessary to obtain a volume of 100 ml fat injected the procedure will be repeated. all sessions will be performed under general anesthesia in day surgery. three month later the patients will undergo breast reconstruction with expander prosthesis. those patients that are randomized to not undergo pre-treatment will undergo breast reconstruction with expander prosthesis immediately. after the reconstruction all patients will have as many appointments as necessary for expansion with a breast nurse at our clinic. if necessary the patient will also meet the surgeon. after the month the patients have a routine doctors appointment. after 6, 12 and 24 month the patients will be followed up with objective measurements of breast symmetry and they will fill in quality of life formularies. in this study we are using the validated formulary called breast q and a study specific formulary. at 24 month standardized photos of the breasts will be taken.

Eligibility criteria:
inclusion criteria: * previously undergone mastectomy and adjuvant radiotherapy. * will undergo breast reconstruction with expander prosthesis. * mammogram and ultrasound performed maximum three month prior surgery. * at least one year since last operation or radiotherapy. exclusion criteria: * known breast cancer relapse * distant metastases except axillary * any contraindication for anaesthesia * systemic disease such as diabetes mellitus type i. * bmi \>30 (if the patients lose weight they are eligible)

Keywords: mammaplasty transplantation, autologous mastectomy breast implants radiotherapy, adjuvant
influence of physical exercise as adjuvant treatment in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the goal of this non-randomized clinical trial is to assess the effects of strength training in the physical function of alzheimer's disease (ad) patients. the main question it aims to answer are: 1. is a basic strength training enough to improve physical function in ad patients? 2. is an exercise intervention able to delayed the progression of the disease? 3. is an amrap intervention feasible in ad patients? participants in the exercise group will perform a 16-weeks program divided in two phases (phase 1: basic strength training; phase 2: amrap training). participants in both (exercise and control) groups will receive their usual care treatments which include occupational therapy, musicotherapy, cognitive stimulation and sensory stimulation.


Eligibility criteria:
inclusion criteria: * mmse (mini-metal state examination) score of ≥15 out of 35 (at screening less than 2 months prior to baseline visit) * age ≥60 years old * be able to walk with or without aids * be able to follow verbal instructions exclusion criteria: * surgery in the last 3 months * exhibit clear signs of disorientation * clinically confirmed signs of aggressiveness

Keywords: dementia physical exercise locomotion
a center based early intervention program for preschoolers with developmental disorders

Conditions: Development Disorder, Child; Developmental Disability; Development Delay; Autism Spectrum Disorder

Summary: the purpose of this study is to examine the effectiveness of a 12-week early intervention program that will include 12 weekly hours in an intensive center-based preschool environment or in the home to treat social communication deficits in children with developmental disorders. the study will include children with developmental disorders, such as autism spectrum disorder, neurogenetic disorders, or intellectual disability.


Eligibility criteria:
inclusion criteria: * diagnosis of developmental disorder, such as autism spectrum disorder, neurogenetic disorder, or intellectual disability, based on clinical interview; * boys and girls between 2.0 years and 5.11 years at time of enrollment; * ability to participate in the testing procedures to the extent that valid standard scores can be obtained. exclusion criteria: * current or lifetime diagnosis of severe psychiatric disorder (e.g., bipolar disorder, etc.); * lack of availability during program hours.
diagnosing variable primary aldosteronism.

Conditions: Primary Aldosteronism; High Blood Pressure

Summary: the goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with primary aldosteronism.

the main questions it aims to answer are: * can we diagnose more people if we used 24 hour urine measurements? * in those with high amounts of aldosterone in their urine, is there a variable pattern to their aldosterone production? participants will have a 24 hour urine measurement. they will also have multiple blood tests throughout the day to study the variability in aldosterone secretion.

Eligibility criteria:
inclusion criteria: * people with clinically suspected pa but have not met criteria for diagnosis. suspicion based on low-renin (renin activity \ 140mmol/l or plasma potassium \< 4mmol/l. * patients who have been diagnosed with pa and had previous aldosterone samples \<277 pmol/l, a level which would normally not qualify for confirmatory testing. * patients with aldosterone results done at different times that indicate variability in production. * willing to consent and participate in the study. exclusion criteria: * inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks. * people on end of life treatment.
a study to evaluate the pharmacokinetics and safety between single administration of "br6002" and coadministration of "br6002a" and "br6002b" under fasting conditions in healthy adult volunteers

Conditions: Gastric or Duodenal Ulcers

Summary: the purpose of this clinical trial is to evaluate the pharmacokinetics and safety between single administration of "br6002" and coadministration of "br6002a" and "br6002b" under fasting conditions in healthy adult volunteers


Eligibility criteria:
inclusion criteria: * those who weigh 55 kg or more for men and 50 kg or more for women and have body mass index (bmi) within the range of 18.0 to 30.0kg/m2 at screening visit. * those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception (in the case of a female subject, hormone drugs is excluded) accepted in clinical trial from the date of the first administration of the investigational products to 7 days after the last administration and disagrees to provide their sperm or ovum. \*methods of contraception accepted in clinical trial: combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. * those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the investigational products, expected adverse events, etc. exclusion criteria: * those who have clinically significant diseases or past history of the gastrointestinal system, cardiovascular system, endocrine system, respiratory system, hemato-oncologic disease, infectious disease, kidney \& genitourinary system, neuropsychiatric system, musculoskeletal system, immune system, ent system, skin system, ophthalmic system. * those who have a medical history of gastrointestinal surgery (except for simple appendectomy, hernia surgery) or gastrointestinal diseases that may affect the absorption of drugs. * those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 1 month prior to the first day of administration or have taken etc, otc, herbal medicine and health functional foods concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as interaction of investigational products, half-life of concomitant drugs) * those who have participated in other clinical trials or bioequivalence tests and administered their investigational products within 6 months prior to the first administration date. * in the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
unstable angina pectoris trial

Conditions: Angina, Unstable; Cardiovascular Diseases; Coronary Disease; Heart Diseases; Myocardial Ischemia

Summary: to compare the efficacy of medical or surgical (coronary artery bypass graft) therapy with regard to survival and quality of life in patients with unstable angina and requisite coronary anatomy as defined by angiography.

background: angina pectoris is a symptomatic condition of attacks of chest pain, often debilitating. it is caused by a decreased supply of blood to the heart, such as that which might occur in coronary artery disease. the usual treatment of angina pectoris is designed to relieve the symptoms. it includes avoidance of activities that produce the discomfort and the use of nitroglycerin and beta blocking drugs. soon after the introduction of coronary bypass surgery, many doctors enthusiastically adopted this approach in treating patients with unstable angina. in 1972, emphasizing that there was no definitive evidence showing the superiority of intensive medical management or coronary bypass surgery in determining mortality and morbidity in patients hospitalized with unstable angina, some of the participating groups in the nhlbi myocardial infarction research units developed a cooperative clinical trial to compare these medical and surgical approaches to therapy. from 1972 through 1976, 288 patients were entered into this randomized clinical trial. one hundred forty-seven patients received intensive pharmacological medical therapy, and 141 comparable patients underwent coronary artery bypass surgery. careful follow-up studies were performed on patients in both groups, in-hospital and during the post-hospital phase. these studies included, apart from routine physical examinations, resting electrocardiograms, chest x-ray films, and grade exercise tolerance tests at six months and twelve months. design narrative: randomized, non-blind, sequential design with a control group and an experimental group. the patients in the experimental group were treated with coronary bypass surgery. patients in the control group received intensive medical management. endpoints were mortality and morbidity measures, such as incidence of myocardial infarction and persistence of angina.

Eligibility criteria:
men and women, ages 21 to 65. angina pectoris (class iii or class iv) at rest or with minimal exercise.
study of comparison between pentacam and locs3

Conditions: Cataract

Summary: hypothesis: there is no difference between pentacam scheimpflug system and locs3 in grading of cataract. major aims: 1. research the efficiency of pentacam scheimpflug system in lens density measurment. 2. to compare the pentacam with the locs3 in grading of cataract.


Eligibility criteria:
inclusion criteria: * cataract patient * age\>18 exclusion criteria: * pregnant women * any disease of the eye except for cataract * patients who are ineligible by law to take decisions by themselves.patients who have a custodian.

Keywords: cataract locs3 pentacam
timing of venous thromboembolism prophylaxis in patients with hypertensive intracerebral hemorrhage

Conditions: Venous Thromboembolism; Pulmonary Embolism; Intracerebral Hemorrhage; Deep Vein Thrombosis

Summary: the objective of this randomized clinical trial is to evaluate the safety and efficiency of different anticoagulation schemes with heparin for venous thromboembolism prevention in patients with hypertensive intracerebral hemorrhage. the main questions it aims to answer are: * what is the optimal time for the beginning of anticoagulation with heparin to efficiently prevent venous thromboembolism in patients with hypertensive intracerebral hemorrhage? early beginning (within the first 2 days but not earlier than 12 hours after the admission of a patient) or delayed beginning (on the third day after the admission of a patient)? * which of the two timeframes (early or delayed) for anticoagulation beginning is the most safe in terms of bleeding complications including intracerebral hemorrhage expansion? researchers will compare the results of early and delayed start of anticoagulation using heparin in patients with hypertensive intracerebral hemorrhage to define the optimal start time for anticoagulation that provides the most favourable efficiency/safety profile. participants will: * undergo a computed tomography (ct) scan of the brain on hospital admission and then 12-24 hours after the hospital admission and 24 hours after the beginning of venous thromboembolism prophylaxis using heparin; * undergo the ultrasound examination of lower extremity deep veins on hospital admission and then once every 7 days; * receive prophylactic doses of low molecular weight heparin or unfractionated heparin either beginning within the first 2 days but not earlier than 12 hours after the hospital admission or starting on the 3rd day after the hospital admission.


Eligibility criteria:
inclusion criteria: * the presence of hypertensive intracerebral hemorrhage exclusion criteria: * intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin) * being on an anticoagulant during preadmission period and on day of hospital admission * death within the first 2 days after hospital admission * detection of venous thromboembolism in a patient at the moment of hospital admission * surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin * the presence of a malignancy (cancer) in a patient at the moment of hospital admission

Keywords: prophylaxis deep vein thrombosis pulmonary embolism venous thromboembolism intracerebral hemorrhage anticoagulation low molecular weight heparin unfractionated heparin
does post-operative rinsing with a monoject syringe result in as much post-operative pain after surgical removal of lower impact third molars as no post-operative rinsing: a randomized controlled equivalence trial

Conditions: Third Molar

Summary: many authors have advocated different methods of treating alveolar osteitis. despite many years of research, however, little progress has been made and so a study with large enough sample and standard outcome measures is warranted. goal of this study is assess the effect of postoperative use of a monoject syringe on postoperative complaints after surgical removal of a lower third molar.

one of the most common postoperative complications after the removal of a third molar is a condition known as dry socket. this term has been in use since 1896. since then several other terms have been used, including alveolar osteitis, postoperative alveolitis, alveolitis, sicca dolorosa and fibriniolytic alveolitis. bim labelled the complication fibrinolytic alveolitis which is the most accurate of the terms, but also the least used. the condition has generally been characterised by delayed healing associated with degradadtion of clot, and is usually accompanied by persistent, radiating, pain postoperativively in and around the extraction site that is not easily relieved by analgesics. because of the pain, swelling and trismus, patients also tend to have a greater need for painkillers. if it is possible to reduce the amount and severity of postoperative pain felt by patients the postoperative period would be more endurable, the quality of life will be less affected, and in addition to this it is possible that the amount of analgesics taken by patients after surgery could be lowered7. it can be a burden for both patients an surgeons and my result in a loss of productivity because at least 45% of patients require multiple visits to the surgeon. objective of the study: many authors have advocated different methods of treating alveolar osteitis. despite many years of research, however, little progress has been made and so a study with large enough sample and standard outcome measures is warranted. goal of this study is assess the effect of postoperative use of a monoject syringe on postoperative complaints after surgical removal of a lower third molar

Eligibility criteria:
inclusion criteria: * in order to be eligible to participate in this study, a subject must meet all of the following criteria: patients over 18 years of age (non-smoking) referred for removal of a wisdom tooth in the mandible. patient has asa i. exclusion criteria: * patient is younger than 18 years patient has an asa of ii,iii en iv patient has only one maxillary third molar that needs to be extracted/removed patient has an active pericoronitis in case of planned coronectomy patient has trismus patient has chronic pain patient is pregnant patient has a known allergy for ibuprofen of other nsaid's patient has a known allergy for articaine of epinefrine intra-operative compilations for example excessive bleeding